Valuation dashboard for Regeneron Pharmaceuticals, Inc. (REGN) with P/E 18.61, P/B 2.54, EV/EBITDA 13.82 and dividend yield 0.47%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses.
Analysis Summary
Regeneron Pharmaceuticals, Inc. reported revenue of $14.34B in the most recent fiscal year, growing at a 5-year CAGR of 11.0%. Net income reached $4.50B, with a 5.1% 5-year CAGR.
Trailing-twelve-month margins: gross margin 84.9%, operating margin 25.6%, net margin 27.9%.
At the current price of $784.85, REGN trades at a P/E of 18.61 and an ROE of 13.81%. Market capitalisation stands at $80.9B, placing it among large-cap names.
Balance sheet quality for REGN: current ratio of 4.1. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| P/E Ratio | 18.61 |
| Price / Book | 2.54 |
| EV / EBITDA | 13.82 |
| Dividend Yield | 0.47% |
Valuation Models
| DCF Fair Value | $1879.25 |
| vs Current Price | +139.4% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| REGN | Regeneron Pharmaceuticals, Inc. | $80.9B | 18.61 | 2.54 | 13.8% |
| ARGX | argenx SE | $61.6B | 36.12 | 7.36 | 21.7% |
| IDXX | IDEXX Laboratories, Inc. | $40.4B | 35.80 | 25.32 | 72.0% |
| ALNY | Alnylam Pharmaceuticals, Inc. | $32.1B | 38.77 | 23.27 | 93.6% |
| INCY | Incyte Corporation | $25.4B | 15.83 | 4.06 | 24.9% |
| GMAB | Genmab A/S | $21.3B | 26.90 | 3.55 | 13.6% |
| CI | Cigna Corporation | $72.7B | 11.48 | 1.72 | |
| ELV | Elevance Health Inc. | $89.1B | 18.16 | 1.98 | 12.9% |
Price
| Price | $784.85 |
| Market Cap | $80.9B |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | 13.81% |
| Return on Invested Capital | 9.19% |
| Return on Assets | 10.37% |
| Gross Margin | 84.86% |
| Operating Margin | 25.56% |
| Net Margin | 27.86% |
Related companies: ALNY · ARGX · CI · COR · ELV · GMAB · IDXX
Explore sector: Healthcare · Biotechnology
More sections of REGN: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks